Published in Am J Hematol on September 12, 2013
Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood (2015) 1.42
Synergy Between Tissue Factor and Exogenous Factor XIa in Initiating Coagulation. Arterioscler Thromb Vasc Biol (2016) 0.76
Adverse effects of immunoglobulin G therapy: thromboembolism and haemolysis. Clin Exp Immunol (2014) 0.75
Nonclinical aspects of venous thrombosis in pregnancy. Birth Defects Res C Embryo Today (2015) 0.75
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA (2009) 5.58
Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet (2009) 4.07
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
Inhibitory effects of B cells on antitumor immunity. Cancer Res (2006) 2.57
Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med (2014) 2.41
Child abuse and neglect--is it time for a public health approach? Aust N Z J Public Health (2008) 2.20
Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol (2008) 2.03
Perspectives on the use of data mining in pharmaco-vigilance. Drug Saf (2005) 2.00
Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis (2008) 2.00
Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA (2005) 1.84
Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet (2013) 1.82
A novel technique of retrograde nasal intubation for the Pierre Robin Sequence infant with a known difficult airway. Paediatr Anaesth (2009) 1.80
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J (2004) 1.76
The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf (2012) 1.73
Measuring coverage in MNCH: design, implementation, and interpretation challenges associated with tracking vaccination coverage using household surveys. PLoS Med (2013) 1.73
Efficacy of radiofrequency ablation for twin-reversed arterial perfusion sequence. Am J Obstet Gynecol (2007) 1.70
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. MMWR Surveill Summ (2003) 1.70
Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010. Transfusion (2012) 1.66
Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem (2002) 1.63
Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics (2008) 1.63
Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol (2005) 1.59
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood (2012) 1.57
Adverse events after anthrax vaccination reported to the Vaccine Adverse Event Reporting System (VAERS), 1990-2007. Vaccine (2008) 1.48
Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem (2009) 1.47
Chart-confirmed guillain-barre syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009-2010. Am J Epidemiol (2013) 1.46
Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol Med Microbiol (2004) 1.46
Anesthesia for in utero repair of myelomeningocele. Anesthesiology (2013) 1.45
Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008 to 2012. Transfusion (2014) 1.45
Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine (2009) 1.40
Posttransfusion purpura occurrence and potential risk factors among the inpatient US elderly, as recorded in large Medicare databases during 2011 through 2012. Transfusion (2014) 1.40
Text mining for the Vaccine Adverse Event Reporting System: medical text classification using informative feature selection. J Am Med Inform Assoc (2011) 1.36
N-terminal proteolysis of full-length mutant huntingtin in an inducible PC12 cell model of Huntington's disease. Cell Cycle (2007) 1.31
Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Am J Epidemiol (2012) 1.28
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis (2008) 1.18
Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul Fibrinolysis (2004) 1.17
Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin. Neurobiol Dis (2006) 1.14
Spatial propagation and localization of blood coagulation are regulated by intrinsic and protein C pathways, respectively. Biophys J (2005) 1.12
Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent. J Immunol (2003) 1.12
Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model. Hum Mol Genet (2010) 1.12
Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol (2005) 1.11
Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol (2004) 1.11
Comparing data mining methods on the VAERS database. Pharmacoepidemiol Drug Saf (2005) 1.10
Prevalence and predictors of smoking behavior among Vietnamese men living in California. Nicotine Tob Res (2005) 1.08
Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease. Neurobiol Dis (2008) 1.05
Task-oriented modular decomposition of biological networks: trigger mechanism in blood coagulation. Biophys J (2010) 1.03
Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza A strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog (2011) 1.01
Vaccine adverse event text mining system for extracting features from vaccine safety reports. J Am Med Inform Assoc (2012) 1.01
PC12 cell model of inducible expression of mutant DISC1: new evidence for a dominant-negative mechanism of abnormal neuronal differentiation. Neurosci Res (2007) 0.99
Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiol Aging (2006) 0.99
Using simulation to assess the sensitivity and specificity of a signal detection tool for multidimensional public health surveillance data. Stat Med (2005) 0.98
Development and characterization of a new Parkinson's disease model resulting from impaired autophagy. J Neurosci (2012) 0.97
Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine (2006) 0.95
A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. Pediatrics (2003) 0.95
Use of toll-like receptor assays to detect and identify microbial contaminants in biological products. J Clin Microbiol (2009) 0.95
Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine (2007) 0.94
Aptamers as a sensitive tool to detect subtle modifications in therapeutic proteins. PLoS One (2012) 0.94
Safety review of the purified chick embryo cell rabies vaccine: Data from the Vaccine Adverse Event Reporting System (VAERS), 1997-2005. Vaccine (2007) 0.94
Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopathies. Acta Neuropathol (2002) 0.93
Surveillance for Guillain-Barré syndrome after influenza vaccination among the Medicare population, 2009-2010. Am J Public Health (2012) 0.93
Recombinant adeno-associated virus serotype 2 vectors mediate stable interleukin 10 secretion from salivary glands into the bloodstream. Hum Gene Ther (2002) 0.93
Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics (2011) 0.93
Neurologic abnormalities in workers of a 1-bromopropane factory. Environ Health Perspect (2004) 0.92
The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf (2012) 0.92
Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA (2004) 0.92
Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics (2005) 0.91
Impact of medical homes on quality, healthcare utilization, and costs. Am J Manag Care (2012) 0.91
Application of information retrieval approaches to case classification in the vaccine adverse event reporting system. Drug Saf (2013) 0.91
Kawasaki disease after vaccination: reports to the vaccine adverse event reporting system 1990-2007. Pediatr Infect Dis J (2009) 0.90
Adverse perinatal outcomes among interracial couples in the United States. Obstet Gynecol (2005) 0.90
Effects of stratification on data mining in the US Vaccine Adverse Event Reporting System (VAERS). Drug Saf (2008) 0.90
Zidovudine and perinatal human immunodeficiency virus type 1 transmission: a population-based approach. Pediatrics (2002) 0.90
A stock-and-flow simulation model of the US blood supply. Transfusion (2013) 0.90
Brucella abortus bacA mutant induces greater pro-inflammatory cytokines than the wild-type parent strain. Microbes Infect (2006) 0.89
Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf (2007) 0.89
A global regulatory science agenda for vaccines. Vaccine (2013) 0.89
Validation of anaphylaxis in the Food and Drug Administration's Mini-Sentinel. Pharmacoepidemiol Drug Saf (2013) 0.87
X-Linked inhibitor of apoptosis protein is involved in mutant SOD1-mediated neuronal degeneration. J Neurochem (2002) 0.87
Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. Stud Health Technol Inform (2011) 0.87
Adverse event reports following vaccination for Lyme disease: December 1998-July 2000. Vaccine (2002) 0.86